Exploring approaches for value-based reimbursement of oncology therapies
1201 Pennsylvania Ave, NW, Suite 500, Washington, DC 20004
October 3, 2017

Workshop goal: The goal of this workshop is to identify steps to enhance the success of value-based payment models for cancer care, with an emphasis on payments to drug manufacturers that better align with provider alternative payment approaches, aiming to improve outcomes and avoid inefficient and low-value spending for cancer patients.

9:00 a.m. Welcome and Introductions
Gregory Daniel, Duke-Margolis Center for Health Policy

9:15 a.m. Session I: Promising approaches for broad implementation of alternative payment models in oncology care
Objective: This session will highlight the benefits and challenges of alternative payment models in oncology.

Moderator: Gregory Daniel, Duke-Margolis Center for Health Policy

- Opening presentation:
  - Diana Verrilli, McKesson Specialty Health
  - William Shrank, UPMC
- Moderated group discussion

Questions to address:
- What are key challenges, specific to oncology care, to adapting alternative payment model (APM) approaches?
- Where are the emerging best practices? What might be generalizable from these case examples?
- How are clinical pathways being used to manage care and drug utilization?
- How are accountable care payment models (oncology care model, episode payments, ACOs, etc) being used to improve cancer care?
- What are priorities for addressing key challenges, scaling best practices, and reimbursing for value in oncology care?

10:00 a.m. Session II: Provider – Payer APMs in Oncology: Identifying successful approaches
Objective: This session will discuss how to leverage promising APM approaches to integrate drugs into payer-provider contracts using recent value-based payment models as case studies.

Moderator: Mark McClellan, Duke-Margolis Center for Health Policy

- Panelists:
  - Chris Ritter, Centers for Medicare & Medicaid Services
Bruce Gould, Northwest Georgia Oncology
Lee Newcomer, UnitedHealthcare

Moderated group discussion

Questions to address:
- Are there features of the agreements that could lead to better aligned incentives?
- How can these approaches best support high-value drug use?
- How can these approaches be leveraged to better include drugs in the value equation?
- What role can manufacturers have in supporting these payment models?
- How can patient preferences be incorporated into these models?

11:00 a.m. Break

11:15 p.m. Session III: Exploring the role of manufacturers in supporting value-based approaches
Objective: This session will identify promising approaches for implementing APMs in oncology between manufacturers and payers as well as discuss how manufacturers can support broader implementation of value-based care.

Moderator: Gregory Daniel, Duke-Margolis Center for Health Policy

- Panelists:
  - John Fox, Priority Health
  - Marc Watrous, Genentech
  - Josh Ofman, Amgen
- Moderated group discussion

Questions to address:
- How can agreements between manufacturers and payers drive toward higher value care?
- Since providers who purchase the oncology medications may also be implementing APMs, what is the manufacturers’ role and how can it be redefined?
- How can manufacturers share the risk that providers assume to use their products?
- How can value based payments best reflect patient preferences and values?
- What are the opportunities to align/support APMs that providers are taking on?

12:15 p.m. Lunch

1:15 p.m. Session IV: Benefit design and patient perspective
Objective: Patients often pay a set out-of-pocket rate for their drugs regardless of whether the drug is reimbursed through an APM/VBP. This session will explore how the structure of benefit design could be impacted by value-based approaches and identify opportunities for alignment.
Questions to address:

- How can patient out-of-pocket expenses be aligned with value-based reimbursement for drugs?
- How can pathways, APMs, and VBPs affect patient access?

2:15 p.m.
Break

2:30 p.m.
Session V: Outcomes, data, and evidence for judging real world value

2:30 p.m.
Sub-session Va: Arriving at meaningful outcomes
Objective: In order to better align payments for therapies with value, all stakeholders must agree on the most appropriate value definition and outcomes to measure. However, it is often difficult to reach consensus on meaningful outcomes; those that are currently available may only be applicable to a limited set of situations.

Moderator: Mark McClellan, Duke-Margolis Center for Health Policy

- Panelists:
  - Laurent Carter, Bristol Myers Squibb
  - Karen Fields, Moffitt Cancer Center
  - Peter Bach, Memorial Sloan Kettering
- Moderated group discussion

Questions to address:

- What are the most common and useful outcome and cost measures in cancer care?
- What are the most important, feasible priorities for augmenting these measures?
- What are areas of disagreement on outcomes and value?
- What are strategies for working with patients to determine meaningful benefit?

3:30 p.m.
Sub-session Vb: Information availability and standards
Objective: The data generated on the efficacy of drugs through clinical trials represents the best case scenario as many sources of variability have been removed. However, when therapies are used in the real world, clinical trial results are hard to replicate and the standards by which a drug is judged may be impractical. Real world data are needed to understand the performance and value of a drug. This sub-session will address the key aspects needed to develop more realistic goals.

Moderator: Mark McClellan, Duke-Margolis Center for Health Policy
Panelists:
  o Bob Miller, Cancer LinQ
• Moderated group discussion

Questions to address:
• What are the most important next steps for improving real-world data and real-world evidence relevant to improving cancer payments and care?
• How will data be collected to enable meaningful conclusions?
• How might providers be reimbursed/incentivized for their role in data collection, drug administration, and measurement?
• How can the burden of data capture be mitigated?

4:00 p.m.  Summary of Key Themes and Next Steps
Mark McClellan, Duke-Margolis Center for Health Policy

4:15 p.m.  Closing Remarks
Mark McClellan, Duke-Margolis Center for Health Policy

4:30 p.m.  Adjournment
Funding for this conference was support in part by a grant from Eli Lilly & Co.